The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey (Q43713389)

26 November 2017

title

The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey (English)

1 reference

26 November 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22750078

5 January 2025

author name string

Donnie Eddins

7

1 reference

26 November 2017

Monika Kandebo

9

1 reference

26 November 2017

Lihang Yao

10

1 reference

26 November 2017

Sean M. Smith

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22750078

5 January 2025

Jason M. Uslaner

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22750078

5 January 2025

Christopher D. Cox

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22750078

5 January 2025

Sarah L. Huszar

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22750078

5 January 2025

Christopher E. Cannon

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22750078

5 January 2025

Joshua D. Vardigan

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22750078

5 January 2025

Dawn M. Toolan

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22750078

5 January 2025

Izzat T. Raheem

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22750078

5 January 2025

John D. Schreier

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22750078

5 January 2025

Michael J. Breslin

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22750078

5 January 2025

Paul J. Coleman

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22750078

5 January 2025

John J. Renger

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22750078

5 January 2025

language of work or name

1 reference

27 June 2012

1 reference

full work available at URL

26 November 2017

https://api.elsevier.com/content/article/PII:S0028390812002717?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

https://api.elsevier.com/content/article/PII:S0028390812002717?httpAccept=text/plain

5 January 2025

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

5 January 2025

1 reference

26 November 2017

volume

64

1 reference

26 November 2017

page(s)

215-223

1 reference

Historical development of the dopamine hypothesis of schizophrenia

26 November 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use

5 January 2025

2

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance

5 January 2025

3

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses

5 January 2025

5

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

D(1) dopamine receptor stimulation increases GluR1 phosphorylation in postnatal nucleus accumbens cultures

5 January 2025

6

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Verbal declarative memory dysfunction in schizophrenia: from clinical assessment to genetics and brain mechanisms

5 January 2025

7

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species

5 January 2025

8

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs

5 January 2025

9

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP)

5 January 2025

10

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Successful performance by monkeys with lesions of the hippocampal formation on AB and object retrieval, two tasks that mark developmental changes in human infants

5 January 2025

11

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Dissociation in prefrontal cortex of affective and attentional shifts

5 January 2025

12

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A)

5 January 2025

13

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Dynamic regulation of glutamatergic postsynaptic activity in rat prefrontal cortex by repeated administration of antipsychotic drugs.

5 January 2025

14

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Working memory dysfunction in schizophrenia

5 January 2025

15

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia

5 January 2025

16

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

What are the functional consequences of neurocognitive deficits in schizophrenia?

5 January 2025

17

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria

5 January 2025

18

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade

5 January 2025

19

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive funct

5 January 2025

22

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia

5 January 2025

23

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Object retrieval/detour deficits in monkeys produced by prior subchronic phencyclidine administration: evidence for cognitive impulsivity

5 January 2025

24

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial

5 January 2025

25

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

NIMH-MATRICS survey on assessment of neurocognition in schizophrenia

5 January 2025

26

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling

5 January 2025

27

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Isolation and characterization of PDE10A, a novel human 3', 5'-cyclic nucleotide phosphodiesterase

5 January 2025

28

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Removing obstacles in neuroscience drug discovery: the future path for animal models

5 January 2025

29

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy

5 January 2025

31

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Mechanisms for the Modulation of Dopamine D1 Receptor Signaling in Striatal Neurons

5 January 2025

33

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: biochemical and behavioral profiles of phosphodiesterase inhibition in dopaminergic neurotransmission

5 January 2025

34

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Basal ganglia pathology in schizophrenia: dopamine connections and anomalies.

5 January 2025

35

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats

5 January 2025

36

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Selective phosphodiesterase inhibitors improve performance on the ED/ID cognitive task in rats.

5 January 2025

37

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia

5 January 2025

38

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Immunohistochemical localization of PDE10A in the rat brain

5 January 2025

39

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Brain receptors for antipsychotic drugs and dopamine: direct binding assays

5 January 2025

40

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

The cell biology of synaptic plasticity: AMPA receptor trafficking

5 January 2025

41

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia.

5 January 2025

42

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.

5 January 2025

43

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function.

5 January 2025

44

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Regulation of phosphorylation of the GluR1 AMPA receptor in the neostriatum by dopamine and psychostimulants in vivo

5 January 2025

46

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A

5 January 2025

47

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Cognitive and motor deficits in the performance of an object retrieval task with a barrier-detour in monkeys (Cercopithecus aethiops sabaeus) treated with MPTP: long-term performance and effect of transparency of the barrier

5 January 2025

49

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Inhibition of Phosphodiesterase 10A Increases the Responsiveness of Striatal Projection Neurons to Cortical Stimulation

5 January 2025

50

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

The evolution of antipsychotic switch and polypharmacy in natural practice--a longitudinal perspective

5 January 2025

51

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

5 January 2025

Schizophrenia

52

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats

5 January 2025

53

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects

5 January 2025

54

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Different contributions of the hippocampus and perirhinal cortex to recognition memory.

5 January 2025

55

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Contrasting effects of excitotoxic lesions of the prefrontal cortex on the behavioural response to D-amphetamine and presynaptic and postsynaptic measures of striatal dopamine function in monkeys

5 January 2025

56

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase

5 January 2025

58

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia

5 January 2025

59

1 reference

https://api.crossref.org/works/10.1016/J.NEUROPHARM.2012.06.013

5 January 2025

Identifiers

1 reference

26 November 2017

1 reference